Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | LIN28A | Q9H9Z2 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.49 |
| ▸ | SYK | P43405 | 3/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.46 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27710379 | 0.98 | SMN1; SMN2 (0.50) | HRH1SMN1; SMN2ALDH1A1KDM4EMAPT | |
| SCHEMBL9673277 | 0.89 | TSHR (0.60) | HRH1SMN1; SMN2ALDH1A1KDM4EMAPT | |
| SCHEMBL2128010 | 0.87 | SMN1; SMN2 (0.46) | HRH1SMN1; SMN2ALDH1A1KDM4EMAPT | |
| SCHEMBL27607904 | 0.87 | SMN1; SMN2 (0.47) | HRH1SMN1; SMN2ALDH1A1KDM4EMAPT | |
| SCHEMBL28304769 | 0.87 | HRH1 (0.55) | HRH1SMN1; SMN2ALDH1A1KDM4EMAPT | |
| SCHEMBL3432856 | 0.87 | SYK (0.46) | HRH1SMN1; SMN2ALDH1A1KDM4EMAPT | |
| Hydrochloric Acid SCHEMBL17654896 | 0.85 | ALDH1A1 (0.47) | HRH1SMN1; SMN2ALDH1A1KDM4EMAPT | |
| SCHEMBL10263927 | 0.83 | KDM4E (0.45) | HRH1SMN1; SMN2ALDH1A1KDM4ELMNA | |
| SCHEMBL8904860 | 0.83 | SMN1; SMN2 (0.47) | HRH1SMN1; SMN2ALDH1A1KDM4EMAPT | |
| SCHEMBL19306253 | 0.83 | SMN1; SMN2 (0.45) | HRH1SMN1; SMN2ALDH1A1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 199 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116148398-A | Method for detecting trace chemical hazard in fat-rich food | 北京市疾病预防控制中心 | 2023-05-23 | — | — | CN | claimed |
| US-20230049294-A1 | STEREOSELECTIVE PROCESS OF MANUFACTURE OF PURINE PHOSPHORAMIDATES | Atea Pharmaceuticals, Inc. (US) | 2023-02-16 | — | — | US | claimed |
| WO-2021216722-A1 | STEREOSELECTIVE PROCESS OF MANUFACTURE OF PURINE PHOSPHORAMIDATES | Atea Pharmaceuticals, Inc. (US) | 2021-10-28 | — | — | WO | claimed |
| CN-104530417-A | Multifunctional H-type polyethylene glycol derivative and preparation method thereof | XIAMEN SINOPEG BIOTECH INC | 2015-04-22 | — | — | CN | claimed |
| CN-104530415-A | Hetero-functionalized Y-type polyethylene glycol derivative, preparation method and biologically related substance thereof | XIAMEN SINOPEG BIOTECH INC | 2015-04-22 | — | — | CN | claimed |
| CN-104109235-A | Mono-functionalized polyethylene glycol with nitrogen atom branched center and its preparation method and biologically-relevant matter | XIAMEN SINOPEG BIOTECH CO LTD | 2014-10-22 | — | — | CN | claimed |
| EP-1546162-B1 | LUMINESCENCE-BASED METHODS AND PROBES FOR MEASURING CYTOCHROME P450 ACTIVITY | PROMEGA CORP (US) | 2011-06-22 | — | — | EP | claimed |
| US-7692022-B2 | Using luciferin derivatives for analyzing metabolic activity in animals, cells or in cell-free reaction formulations | PROMEGA CORPORATION (US) | 2010-04-06 | — | — | US | claimed |
| EP-1546162-A4 | LUMINESCENCE-BASED METHODS AND PROBES FOR MEASURING CYTOCHROME P450 ACTIVITY | PROMEGA CORP (US) | 2007-07-18 | — | — | EP | claimed |
| EP-1546162-A2 | LUMINESCENCE-BASED METHODS AND PROBES FOR MEASURING CYTOCHROME P450 ACTIVITY | PROMEGA CORPORATION (US) | 2005-06-29 | — | — | EP | claimed |
| US-20040171099-A1 | Using luciferin derivatives for analyzing metabolic activity in animals, cells or in cell-free reaction formulations | PROMEGA CORPORATION | 2004-09-02 | — | — | US | claimed |
| WO-2004027378-A2 | LUMINESCENCE-BASED METHODS AND PROBES FOR MEASURING CYTOCHROME P450 ACTIVITY | PROMEGA CORPORATION (US) | 2004-04-01 | — | — | WO | claimed |
| US-12551499-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4604951-A1 | 1-(SULFONYL)-N-PHENYLPYRROLIDINE-2-CARBOXAMIDES DERIVATIVES AND USE THEREOF | AMIRA THERAPEUTICS, S.L. (ES) | 2025-08-27 | — | — | EP | disclosed |
| CN-113454124-B9 | Combination therapies for ARM and natural killer cells | 克莱奥药品有限公司 | 2025-05-30 | — | — | CN | disclosed |
| CN-113454124-B | Combination therapies for ARM and natural killer cells | 克莱奥药品有限公司 | 2025-03-11 | — | — | CN | disclosed |
| US-4746648-A | HYPOTENSIVE, ANTIULCER | Sanofi, Institut National de la Recherche Medicale (FR) | 1988-05-24 | — | — | US | disclosed |
| US-4728668-A | Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments | USV PHARMACEUTICAL CORPORATION (US) | 1988-03-01 | — | — | US | disclosed |
| US-4725619-A | Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments | USV PHARMACEUTICAL CORPORATION (US) | 1988-02-16 | — | — | US | disclosed |
| US-4631287-A | Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments | USV PHARMACEUTICAL CORP. (US) | 1986-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12551499-B2 | Highly active compounds against COVID-19 | PNP, SLC29A2, MTAP | HRH1 3321/4885SMN1; SMN2 1054/4885ALDH1A1 1808/4885 |
| US-20230049294-A1 | STEREOSELECTIVE PROCESS OF MANUFACTURE OF PURINE PHOSPHORAMIDATES | NUDT1, PNP, ITPA | HRH1 1789/4885SMN1; SMN2 1279/4885ALDH1A1 1210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.